Intrathecal pump device is expected to evolve with several companiesworking on new technologies that would improve the functioning ofprogrammable pump, internal mechanism, and safety. In 2014, Food andDrug Administration (FDA) approved the ‘Prometra’ intrathecalpump launched by Flowonix Medical Inc. ‘Prometra’ have variousfeatures, such as accurate drug delivery system, dual-gated valvedrug distribution, and improved device durability. The other area ofinterest in the intrathecal space is the development of new drugsthat could be delivered to treat specific alignments. For instance,FDA approved number of medications, such as Ziconotide (2004),Spinraza (2016), and probuphine (2016), which have been proven to besafe for intrathecal administration.
The intrathecal pumpand catheters are implanted under the skin surgically to deliver thedrug directly into the spinal cord, which offers dramatic painmanagement. Besides, these pumps are easy to use, portable,accurate, and also consume very less power. World Health Organization(WHO) has estimated that, 1 out 10 adults are newly identified withchronic pain annually. Thus, there exist a huge potential forIntrathecalPumps Market.
Drugs used inintrathecal drug delivery pumps consist mainly of opioids, adrenergicagonists, N-methyl-D-aspartate receptor agonists, local anesthetics,and other agents. As most of the drugs delivered through intrathecalpumps are analgesics, pain management accounts for the largest sharein the global intrathecal pumps market followed by spasticitymanagement.
Read More@https://bit.ly/3wCgAu7
